High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group
暂无分享,去创建一个
M. Pfreundschuh | R. Möhle | J. Finke | E. Valk | I. Schmidt-Wolf | R. Schroers | G. Ihorst | B. Kasenda | L. Baumgarten | M. Binder | G. Egerer | U. Keller | A. Korfel | A. Röth | M. Lamprecht | G. Illerhaus | J. Bloehdorn | K. Fritsch | E. Schorb | H. Fricker
[1] K. Hoang-Xuan,et al. Rituximab-Lenalidomide (REVRI) in Relapse or Refractory Primary Central Nervous System (PCNSL) or Vitreo Retinal Lymphoma (PVRL): Results of a "Proof of Concept" Phase II Study of the French LOC Network , 2016 .
[2] L. Deangelis,et al. Single-Agent Ibrutinib in Recurrent/Refractory Central Nervous System Lymphoma , 2016 .
[3] A. LaCasce,et al. Nivolumab (Anti-PD1) Therapy for Relapsed/ Refractory Primary Central Nervous System Lymphoma and Primary Testicular Lymphoma , 2016 .
[4] E. Thiel,et al. Phase II Trial of Temsirolimus for Relapsed/Refractory Primary CNS Lymphoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] D. Brat,et al. Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Erik L. Clarke,et al. Modeling altered T-cell development with induced pluripotent stem cells from patients with RAG1-dependent immune deficiencies. , 2016, Blood.
[7] R. Pfeiffer,et al. Trends in primary central nervous system lymphoma incidence and survival in the U.S. , 2016, British journal of haematology.
[8] M. Pfreundschuh,et al. High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. , 2016, The Lancet. Haematology.
[9] F. Cavalli,et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. , 2016, The Lancet. Haematology.
[10] A. Ferreri,et al. The role of autologous stem cell transplantation in primary central nervous system lymphoma. , 2016, Blood.
[11] Andrew J. Dunford,et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. , 2014, Blood.
[12] D. Correa,et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] M. Reni,et al. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R‐IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high‐dose methotrexate‐based chemotherapy , 2013, Hematological oncology.
[14] B. Cheson,et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] M. Prados,et al. Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma , 2013, Leukemia & lymphoma.
[16] K. Hoang-Xuan,et al. Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases , 2012, Haematologica.
[17] J. Finke,et al. Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] A. Rademaker,et al. Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma , 2012, Cancer.
[19] M. Fujii,et al. Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy , 2011, Leukemia & lymphoma.
[20] K. Hoang-Xuan,et al. Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma , 2011, Journal of Neuro-Oncology.
[21] E. Thiel,et al. Systemic Relapses In Primary CNS Lymphoma (PCNSL) - Unexpected Clonal Diversity , 2010 .
[22] K. Hoang-Xuan,et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] F. Feuerhake,et al. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system , 2008, Haematologica.
[24] K. Hynynen,et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] F. Feuerhake,et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] E. Thiel,et al. Prospective trial on topotecan salvage therapy in primary CNS lymphoma. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] E. Thiel,et al. Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors , 2006, Journal of Neuro-Oncology.
[28] E. Elkin,et al. Trends in survival from primary central nervous system lymphoma, 1975–1999 , 2005, Cancer.
[29] J. Armitage,et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] W. Mason,et al. Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. , 2004, European journal of cancer.
[31] R. Fimmers,et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] J Crowley,et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.
[33] M Schemper,et al. A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.
[34] D. Osoba,et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.
[35] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.
[36] J. Armitage,et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. , 1987, The New England journal of medicine.
[37] P. Wen,et al. Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma , 2007, Journal of Neuro-Oncology.
[38] K. Hoang-Xuan,et al. [Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma]. , 2004, Bulletin du cancer.